IMNN - Imunon, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
5.11 0.0 (0.0%)	---	---	0.0 (0.0%)	-0.06 (-1.17%)	-0.34 (-6.65%)	0.21 (4.29%)	0.21 (4.29%)

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -2.15
Diluted EPS:: -2.15
Basic P/E:: -2.3767
Diluted P/E:: -2.3767
RSI(14) 1m:: 100.0
VWAP:: 5.11
RVol:: 1.3346

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	5.02 +0.12 (+2.45%)	Oct 15 16:20
1m	Price increase 1m	5.02 +0.12 (+2.45%)	Oct 15 16:20
1m	Price increase 1m	5.02 +0.12 (+2.45%)	Oct 15 16:20
1m	Price increase 1m	5.02 +0.12 (+2.45%)	Oct 15 16:20
1m	Price increase 1m	5.02 +0.12 (+2.45%)	Oct 15 16:20